Michael Dillon is a Senior Scientist in the Sterile Product Development group at Merck Research Labs. In this role, Mike is responsible for late-stage development of biological drug products, primarily antibody drug conjugates, along with previous experience with high concentration mAb formulations in combination products. He is engaged in the predictive stability space for biologics, where he has developed kinetic models to predict the long-term stability of biologics with short term data, and demonstrated the approach on a variety of products and quality attributes as recently published in Molecular Pharmaceutics. This work will be the focus of his talk.